Want to see BYSI full AI Analyst Report?
BYSI Stock Chart & Stats
$1.66
-$0.09(-5.17%)
At close: 4:00 PM EST
$1.66
-$0.09(-5.17%)
Day’s Range― - ―
52-Week Range$1.18 - $2.44
Previous CloseN/A
Volume3.10K
Average Volume (3M)478.07K
Market Cap
$61.27M
Enterprise Value$61.59M
Total Cash (Recent Filing)$7.86M
Total Debt (Recent Filing)$246.00K
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Sep 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding41,119,820
10 Day Avg. Volume1,393,566
30 Day Avg. Volume478,066
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)-2.05
Price to Sales (P/S)0.00
P/FCF Ratio-3.28
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.24K
Enterprise Value/Ebitda-7.68
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.98
Revenue Forecast (FY)$194.65M
Bulls Say, Bears Say
Bulls Say
Lead Asset Phase 3 ProgressionAdvancing plinabulin into a 442‑patient confirmatory Phase 3 is a durable, binary value driver: positive trial results would enable regulatory filings, partner commercialization discussions, and long-term revenue potential. Execution of Phase 3 also focuses R&D priorities and attracts strategic investors.
Improving Loss TrendMaterial narrowing of annual losses over multiple years reflects improved cost discipline and operational efficiency. A sustainable downward trend in losses increases runway per financing, improves credibility with investors and partners, and reduces execution risk versus earlier burn levels.
Low Formal Debt LevelsVery modest reported debt keeps fixed financial obligations low, preserving flexibility for a clinical-stage biotech that will rely on equity/partner funding. Low contractual leverage reduces near-term default risk and supports strategic choices around partnering or milestone-based financings.
Bears Say
Negative Shareholder EquityA persistent negative equity position and a steep decline in assets signal long-term balance‑sheet stress. This constrains financing options, increases dilution risk via equity raises, and may impede partnerships or favorable commercial terms, raising structural solvency and credibility concerns.
Ongoing Negative Operating Cash FlowConsistent annual operating cash deficits create a structural dependence on external funding to complete Phase 3 and commercialize any asset. Regular capital raises dilute shareholders and can interrupt programs; persistent burn increases execution risk if financing windows tighten.
Pre-commercial With Effectively Zero RevenueWith no meaningful product revenue, the company lacks recurring cash generation, leaving valuation and operational continuity contingent on clinical success or partnerships. This structural lack of revenue reduces visibility into long-term cash flows and heightens reliance on external stakeholders.
Beyondspring News
BYSI FAQ
What was Beyondspring Inc’s price range in the past 12 months?
Beyondspring Inc lowest stock price was $1.18 and its highest was $2.44 in the past 12 months.
What is Beyondspring Inc’s market cap?
Beyondspring Inc’s market cap is $61.27M.
When is Beyondspring Inc’s upcoming earnings report date?
Beyondspring Inc’s upcoming earnings report date is Sep 04, 2026 which is in 55 days.
How were Beyondspring Inc’s earnings last quarter?
Beyondspring Inc released its earnings results on May 13, 2026. The company reported -$0.052 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.052.
Is Beyondspring Inc overvalued?
According to Wall Street analysts Beyondspring Inc’s price is currently Overvalued.
Does Beyondspring Inc pay dividends?
Beyondspring Inc does not currently pay dividends.
What is Beyondspring Inc’s EPS estimate?
Beyondspring Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beyondspring Inc have?
Beyondspring Inc has 41,119,820 shares outstanding.
What happened to Beyondspring Inc’s price movement after its last earnings report?
Beyondspring Inc reported an EPS of -$0.052 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.317%.
Which hedge fund is a major shareholder of Beyondspring Inc?
Currently, no hedge funds are holding shares in BYSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beyondspring Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.49%
12-Months-Change
Fundamentals
Return on Equity
23.76%
Trailing 12-Months
Asset Growth
-50.39%
Trailing 12-Months
Company Description
Beyondspring Inc
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
Technical Analysis
Plus Therapeutics
―
X4 Pharmaceuticals
―
ABVC BioPharma
―
Prelude Therapeutics
―
Gain Therapeutics
―
Ownership Overview
10.96% Insiders
2.19% Mutual Funds
9.38% Other Institutional Investors
75.74% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---